ReviewNephrology (Carlton, Vic.)2016
An expanded nationwide view of chronic kidney disease in Aboriginal Australians.
Review in Nephrology (Carlton, Vic.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 66 citations in OpenAlex.
- Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach.Internal medicine journal · 2026Article
- Kidney health outcomes of hypertensive disorders of pregnancy.Nature reviews. Nephrology · 2025Review
- Variability in Dialysis Access Over Time and Across Centres in Australia and New Zealand: Effect of Centre- and Patient-Related Factors on Dialysis Access Quality Indicators.Nephrology (Carlton, Vic.) · 2025Article
- Kidney Function in the Wixarika (Huichol) Ethnic Group, a Disadvantaged Population Underevaluated in Mexico.Kidney medicine · 2025Article
- Classification of chronic kidney disease in older Australian adults by the CKD-EPI 2009 and 2021 equations: secondary analysis of ASPREE study data.The Medical journal of Australia · 2025Article
- Supporting equitable access to kidney transplant in remote Western Australia using continuous quality improvement.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2025Article
- Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?The Journal of antimicrobial chemotherapy · 2024Article
- Article
- Twenty years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population.Clinical kidney journal · 2023Article
- Article
- Article
- Sex differences in mortality among binational cohort of people with chronic kidney disease: population based data linkage study.BMJ (Clinical research ed.) · 2021Article
- Narrative Review of Hyperferritinemia, Iron Deficiency, and the Challenges of Managing Anemia in Aboriginal and Torres Strait Islander Australians With CKD.Kidney international reports · 2021Review
- Kidney failure in Samoa.The Lancet regional health. Western Pacific · 2020Article
- Article
- Progressive Nephron Loss in Aging Kidneys: Clinical-Structural Associations Investigated by Two Anatomical Methods.Anatomical record (Hoboken, N.J. : 2007) · 2020Article
- Protocol and establishment of a Queensland renal biopsy registry in Australia.BMC nephrology · 2020Article
- Female preterm indigenous Australian infants have lower renal volumes than males: A predisposing factor for end-stage renal disease?Nephrology (Carlton, Vic.) · 2019Article
- Observational
- A randomised controlled trial of potential for pharmacologic prevention of new-onset albuminuria, hypertension and diabetes in a remote Aboriginal Australian community, 2008-2013.Contemporary clinical trials communications · 2019Article
Corrections and comments
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We summarize new knowledge that has accrued in recent years on chronic kidney disease (CKD) in Indigenous Australians. CKD refers to all stages of preterminal kidney disease, including end-stage kidney failure (ESKF), whether or not a person receives renal replacement therapy (RRT). Recently recorded rates of ESKF, RRT, non-dialysis CKD hospitalizations and CKD attributed deaths were, respectively, more than sixfold, eightfold, eightfold and threefold those of non-Indigenous Australians, with age adjustment, although all except the RRT rates are still under-enumerated. However, the nationwide average Indigenous incidence rate of RRT appears to have stabilized. The median age of Indigenous people with ESKF was about 30 years less than for non-Indigenous people, and 84% of them received RTT, while only half of non-Indigenous people with ESKF did so. The first-ever (2012) nationwide health survey data showed elevated levels of CKD markers in Indigenous people at the community level. For all CKD parameters, rates among Indigenous people themselves were strikingly correlated with increasing remoteness of residence and socio-economic disadvantage, and there was a female predominance in remote areas. The burden of renal disease in Australian Indigenous people is seriously understated by Global Burden of Disease Mortality methodology, because it employs underlying cause of death only, and because deaths of people on RRT are frequently attributed to non-renal causes. These data give a much expanded view of CKD in Aboriginal people. Methodologic approaches must be remedied for a full appreciation of the burden, costs and outcomes of the disease, to direct appropriate policy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.